Akero Therapeutics
Compare Akero Therapeutics…Efruxifermin (FGF21 analog) for MASH. Novo Nordisk agreed to acquire Akero for $5.2B in late 2025, positioning MASH as combinable with GLP-1.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Akero TherapeuticsEfruxifermin (FGF21 analog) for MASH. Novo Nordisk agreed to acquire Akero for $5.2B in late 2025, positioning MASH as combinable with GLP-1.
Basic shares represent total shares issued. Diluted shares include potential shares from stock options, convertible securities, and other equity awards.
Q4 2017 — Q3 2025(All available data)